Even light drinking may make fatty liver disease worse
New drug may improve liver cancer therapy
The LANCET-EASL Commission on liver diseases in Europe: Overcoming unmet needs, stigma, and inequities
Worldwide, liver diseases are on the rise, yet patients with liver disease are still experiencing stigma, resulting in a barrier to liver disease awareness and inequity in access to appropriate care. The Lancet–EASL…
Viral hepatitis burden in Europe
The HEPAHEALTH Project Report, produced by the European Association for the Study of the Liver (EASL), is the second overview commissioned by EASL on the burden of liver disease in Europe. The report encompasses…
DNA methylation related to liver disease among obese patients, study shows
Researchers have identified how DNA methylation is associated with a condition known as non-alcoholic fatty liver disease (NAFLD), which can lead to liver cirrhosis and death, and is one of the leading…
Predicting the future burden of NAFLD and NASH
While the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) continues to rise, with both conditions increasingly recognised in primary care and specialist practice, quantifying future disease burden has…
Focused ultrasound increases drug delivery to liver tumours
A heat-sensitive liposomal preparation loaded with doxorubicin (multiple brands) was able to deliver its contents directly to liver lesions when the temperature was raised above 39.5 °C by focused ultrasound (FUS), according…